ArticleClinical and experimental medicine2019
FGB and FGG derived from plasma exosomes as potential biomarkers to distinguish benign from malignant pulmonary nodules.
Article in Clinical and experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- The diagnostic and prognostic value of exosome-derived long non-coding RNAs in cancer patients: a meta-analysis.Clinical and experimental medicine · 2020Pooled it
- Impact of Isolation Techniques on the Content of Small Extracellular Vesicles.Journal of extracellular vesicles · 2026Article
- Diagnosis model of early malignant pulmonary nodules based on clinical laboratory data.Scientific reports · 2026Article
- Application of liquid biopsy in differentiating lung cancer from benign pulmonary nodules (Review).International journal of molecular medicine · 2025Review
- Minimally invasive biomarkers for triaging lung nodules-challenges and future perspectives.Cancer metastasis reviews · 2025Review
- Identification of diagnostic and prognostic biomarkers for tuberculosis based on plasma proteomics.PloS one · 2025Article
- Advances in modelling the risk of benign and malignant lung nodules.Frontiers in oncology · 2025Review
- Serum exosomal small nucleolar RNA (snoRNA) signatures as a predictive biomarker for benign and malignant pulmonary nodules.Cancer cell international · 2024Article
- Multi-omic molecular characterization and diagnostic biomarkers for occult hepatitis B infection and HBsAg-positive hepatitis B infection.Frontiers in endocrinology · 2024Article
- Mechanism study of serum extracellular nano-vesicles miR-412-3p targeting regulation of TEAD1 in promoting malignant biological behavior of sub-centimeter lung nodules.Cancer biomarkers : section A of Disease markers · 2024Article
- Identification of exosome protein panels as predictive biomarkers for non-small cell lung cancer.Biological procedures online · 2023Article
- Circ_16601 facilitates Hippo pathway signaling via the miR-5580-5p/FGB axis to promote my-CAF recruitment in the TME and LUAD progression.Respiratory research · 2023Article
- Article
- Article
- The Roles of Exosomal Proteins: Classification, Function, and Applications.International journal of molecular sciences · 2023Review
- A lung cancer risk prediction model for nonsmokers: A retrospective analysis of lung nodule cohorts in China.Journal of clinical laboratory analysis · 2022Article
- Proteomic profiling reveals a distinctive molecular signature for critically ill COVID-19 patients compared with asthma and chronic obstructive pulmonary disease.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- miR-877-5p Inhibits Epithelial Mesenchymal Transformation of Breast Cancer Cells by Targeting FGB.Disease markers · 2022Article
- Combination of CT and telomerase+ circulating tumor cells improves diagnosis of small pulmonary nodules.JCI insight · 2021Article
- Top 100 most-cited articles on exosomes in the field of cancer: a bibliometric analysis and evidence mapping.Clinical and experimental medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Previous proteomic analysis (label-free) of plasma exosomes revealed that the expression of FGG and FGB was significantly higher in the malignant pulmonary nodules group, compared to the benign pulmonary nodules group. The present study was performed to evaluate the role of plasma exosomal proteins FGB and FGG in the diagnosis of benign and malignant pulmonary nodules. We examined the expression levels of FGB and FGG in plasma exosomes from 63 patients before surgery. Postoperative pathological diagnosis confirmed that 43 cases were malignant and 20 cases were benign. The ROC curve was used to describe the sensitivity, specificity, area under the curve (AUC) of the biomarker and the corresponding 95% confidence interval. We confirmed that the expression levels of FGB and FGG were higher in the plasma exosomes of malignant group than in the benign group. The sensitivity and AUC of FGB combined with FGG detection to determine the nature of pulmonary nodules are superior to single FGB or FGG detection. FGB and FGG might represent novel and sensitive biomarker to distinguish benign from malignant pulmonary nodules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.